The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
Open accessAbstract
A robust personalized ctDNA test, TARDIS, achieves high accuracy for residual disease after completion of neoadjuvant therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Haplotype-based variant detection from short-read sequencing
Garrison, E., & Marth, G. (2012) · arXiv · doi:10.48550/arxiv.1207.3907 · Cited by 3,700
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Self-citationSmith, T., Heger, A., & Sudbery, I. (2017) · Genome Research · doi:10.1101/gr.209601.116 · Cited by 2,143
Cited by
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Magbanua, M. J. M., Swigart, L. B., Wu, H.-T., Hirst, G. L., Yau, C., Wolf, D. M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.007 · Cited by 462
Parikh, A. R., Van Seventer, E. E., Siravegna, G., Hartwig, A. V., Jaimovich, A., He, Y., Kanter, K., Fish, M. G., Fosbenner, K. D., Miao, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0410 · Cited by 380
Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance
Kilgour, E., Rothwell, D. G., Brady, G., & Dive, C. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.012 · Cited by 360
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Metadata
- Authors
- McDonald, B. R., Contente-Cuomo, T., Sammut, S.-J., Odenheimer-Bergman, A., Ernst, B., Perdigones, N., Chin, S.-F., Farooq, M., Mejia, R., Cronin, P. A., Anderson, K. S., Kosiorek, H. E., Northfelt, D. W., McCullough, A. E., Patel, B. K., Weitzel, J. N., Slavin, T. P., Caldas, C., Pockaj, B. A., & Murtaza, M.
- Venue
- Science Translational Medicine
- Published
- 2019-08-07
- Volume
- 11
- Issue
- 504
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2965583450
- Cited by
- 305
- References
- 42
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. https://app.cochat.ai/papers/10.1126/scitranslmed.aax7392
- The paper
- McDonald, B. R., Contente-Cuomo, T., Sammut, S.-J., Odenheimer-Bergman, A., Ernst, B., Perdigones, N., Chin, S.-F., Farooq, M., Mejia, R., Cronin, P. A., Anderson, K. S., Kosiorek, H. E., Northfelt, D. W., McCullough, A. E., Patel, B. K., Weitzel, J. N., Slavin, T. P., Caldas, C., Pockaj, B. A., & Murtaza, M. (2019). Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aax7392
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.